Annals of Surgical Oncology

, Volume 20, Issue 2, pp 640–645 | Cite as

Utility of 111Indium-pentetreotide Scintigraphy in Patients with Neuroendocrine Tumors

  • Narek Shaverdian
  • Scott N. Pinchot
  • Barbara Zarebczan
  • Holly C. Gillis
  • Adam Schiro
  • Herbert Chen
Endocrine Tumors



Neuroendocrine (NE) tumors pose a diagnostic challenge with the need to utilize a combination of biochemical analysis, standard cross-sectional imaging, and more recently, nuclear medicine scans such as 111indium–pentetreotide scintigraphy (somatostatin receptor scintigraphy, SRS; OctreoScan, Covidien Imaging Solutions, Hazelwood, MO). In this study we sought to evaluate the clinical utility of scintigraphy in the diagnosis and management of patients with NE tumors at a major university hospital.


A retrospective chart review was performed on all patients who underwent both 111indium–pentetreotide scintigraphy and computed tomography/magnetic resonance imaging (CT/MRI) at a single institution between February 2001 and July 2008. Charts were reviewed for patient demographics, symptoms of NE disease, and results of biochemical testing, imaging studies, histopathologic diagnosis, and medical and/or surgical management.


One hundred forty-five patients received 111indium–pentetreotide scintigraphy (SRS) and concurrent cross-sectional imaging (CT/MRI) over the 7-year period studied. In the evaluation of primary disease, 60 % of tumors were localized by anatomic imaging, significantly greater than the 15 % detection rate achieved by SRS. In the evaluation of recurrent disease, 61 % of NE tumors were localized by cross-sectional imaging, significantly greater than the 31 % detection rate of SRS. Scintigraphy identified disease foci not seen on CT/MRI in just 8 of 74 of the cohort with evidence of disease and only altered the surgical management in 3 of 74 cases.


Cross-sectional CT/MRI imaging is sufficient for the localization of NE tumors. 111Indium–pentetreotide scintigraphy does not significantly alter the surgical management of patients with NE tumors, and we suggest that it be selectively reserved for patients with disease that is occult to cross-sectional imaging.


  1. 1.
    Cooper W, Thourani V, Gal A, et al. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest. 2001;119:14–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med. 2000;44:13–21.PubMedGoogle Scholar
  3. 3.
    Heymann M, Joubert M, Nemeth J, et al. Prognostic and immunohistochemical validation of the capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases. Histopathology. 2000;36:421–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Norton J, Doppman J, Jensen R. Curative resection in Zollinger–Ellison syndrome. Results of a 10-year prospective study. Ann Surg. 1992;215:8–18.PubMedCrossRefGoogle Scholar
  5. 5.
    Mignon M, Bonfils S. Diagnosis and treatment of Zollinger–Ellison syndrome. Baillieres Clin Gastroenterol. 1988;2:677–98.PubMedCrossRefGoogle Scholar
  6. 6.
    Woodside K, Townsend CJ, Mark Evers B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg. 2004;8:742–56.PubMedCrossRefGoogle Scholar
  7. 7.
    Boudreaux J, Putty B, Frey D, et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg. 2005;241:839–45.PubMedCrossRefGoogle Scholar
  8. 8.
    Que F, Sarmiento J, Nagorney D. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Adv Exp Med Biol. 2006;574:43–56.PubMedCrossRefGoogle Scholar
  9. 9.
    Maroun J, Kocha W, Kvols L, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol. 2006;13:67–76.PubMedGoogle Scholar
  10. 10.
    Olsen JO, Pozderac RV, Hinkle G, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (OctreoScan). Semin Nucl Med. 1995;25:251–61.PubMedCrossRefGoogle Scholar
  11. 11.
    Chiti A, van Graafeiland BJ, Savelli G, et al. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues. Ital J Gastroenterol Hepatol. 1999;31(Suppl. 2):S190–4.PubMedGoogle Scholar
  12. 12.
    Tamm E, Kim E, Ng C. Imaging of neuroendocrine tumors. Hematol Oncol Clin North Am. 2007;21:409–32, vii.Google Scholar
  13. 13.
    Lebtahi R, Cadiot G, Srada L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med. 1997;38:853–8.PubMedGoogle Scholar
  14. 14.
    Torpy DJ, Chen N, Mullen JL, et al. Lack of tility of 111In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab. 1999;84:1186–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Saga T, Shimatsu A, Koizumi K, et al. Morphological imaging in the localization of neuroendocrine gastroenteropancreatic tumors found by somatostatin receptor scintigraphy. Acta Radiol. 2005;46:227–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Krishbom PM, Kerani Ar, Onaitis MW, et al. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery. 1998;124:1063–70.CrossRefGoogle Scholar
  17. 17.
    Savelli G, Lucignani G, Sergeni E, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumors. Nucl Med Commun. 2004;25:445–9.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Narek Shaverdian
    • 1
  • Scott N. Pinchot
    • 1
  • Barbara Zarebczan
    • 1
  • Holly C. Gillis
    • 1
  • Adam Schiro
    • 1
  • Herbert Chen
    • 1
  1. 1.Section of Endocrine Surgery, Department of SurgeryUniversity of WisconsinMadisonUSA

Personalised recommendations